Should I buy or sell Emergent BioSolutions stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Emergent BioSolutions in the last year. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" EBS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EBS, but not buy additional shares or sell existing shares. View EBS analyst ratings or view top-rated stocks .

What is Emergent BioSolutions' stock price target for 2024?

2 brokerages have issued 12 month price targets for Emergent BioSolutions' shares. Their EBS share price targets range from $5.00 to $5.00. On average, they predict the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 153.2% from the stock's current price. View analysts price targets for EBS or view top-rated stocks among Wall Street analysts .

How have EBS shares performed in 2024?

Emergent BioSolutions' stock was trading at $2.40 on January 1st, 2024. Since then, EBS shares have decreased by 17.7% and is now trading at $1.9750. View the best growth stocks for 2024 here .

Are investors shorting Emergent BioSolutions?

Emergent BioSolutions saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 5,700,000 shares, an increase of 16.1% from the March 15th total of 4,910,000 shares. Based on an average daily volume of 2,980,000 shares, the days-to-cover ratio is currently 1.9 days. Approximately 11.4% of the company's shares are short sold. View Emergent BioSolutions' Short Interest .

When is Emergent BioSolutions' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our EBS earnings forecast .

How were Emergent BioSolutions' earnings last quarter?

Emergent BioSolutions Inc. (NYSE:EBS) announced its quarterly earnings results on Wednesday, March, 6th. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by $0.44. The biopharmaceutical company had revenue of $276.60 million for the quarter, compared to analysts' expectations of $247.63 million. Emergent BioSolutions had a negative trailing twelve-month return on equity of 37.35% and a negative net margin of 72.11%. During the same period last year, the firm posted ($0.31) earnings per share.

What ETF holds Emergent BioSolutions' stock?

Amplify Treatments, Testing and Advancements ETF holds 14,243 shares of EBS stock, representing 0.70% of its portfolio.

What guidance has Emergent BioSolutions issued on next quarter's earnings?

Emergent BioSolutions issued an update on its first quarter 2024 earnings guidance on Wednesday, March, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $200.0 million-$250.0 million, compared to the consensus revenue estimate of $185.4 million.

What is Bob Kramer's approval rating as Emergent BioSolutions' CEO?

38 employees have rated Emergent BioSolutions Chief Executive Officer Bob Kramer on Glassdoor.com . Bob Kramer has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Emergent BioSolutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent BioSolutions investors own include NVIDIA (NVDA) , Salesforce (CRM) , Novavax (NVAX) , Advanced Micro Devices (AMD) , Block (SQ) , Netflix (NFLX) , Gilead Sciences (GILD) , PayPal (PYPL) , Johnson & Johnson (JNJ) and AbbVie (ABBV) .

Who are Emergent BioSolutions' major shareholders?

Emergent BioSolutions' stock is owned by many different retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.37%). Insiders that own company stock include Kathryn C Zoon, Richard S Lindahl and Ronald Richard. View institutional ownership trends .

How do I buy shares of Emergent BioSolutions?

Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSE:EBS

Emergent BioSolutions (EBS) Stock Price, News & Analysis

→ “Forget Tesla, this is Elon’s Next Big Thing” (From InvestorPlace) (Ad)

Free EBS Stock Alerts

$2.02

+0.04 (+2.02%)

(As of 10:08 AM ET)

Compare

Today's Range: $1.91
▼
$2.03
50-Day Range: $1.49
▼
$3.41
52-Week Range: $1.42
▼
$12.01

Volume: 112,180 shs
Average Volume: 2.78 million shs
Market Capitalization: $105.83 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.00

Get Emergent BioSolutions alerts:

Emergent BioSolutions MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 153.2% Upside
$5.00 Price Target
Short Interest: Bearish
11.38% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.40
Upright™ Environmental Score
News Sentiment: 0.26
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($13.98) to ($0.25) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.93 out of 5 stars

Medical Sector

233rd out of 928 stocks

Pharmaceutical Preparations Industry

96th out of 434 stocks

3.0

Analyst's Opinion

Consensus Rating
Emergent BioSolutions has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.
Amount of Analyst Coverage
Emergent BioSolutions has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
11.38% of the float of Emergent BioSolutions has been sold short.
Short Interest Ratio / Days to Cover
Emergent BioSolutions has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Emergent BioSolutions has recently increased by 16.09%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Emergent BioSolutions does not currently pay a dividend.
Dividend Growth
Emergent BioSolutions does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Emergent BioSolutions has received a 73.60% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Influenza vaccines", "Cholera vaccines", and "Antibiotics" products. See details.
Environmental Sustainability
The Environmental Impact score for Emergent BioSolutions is -1.40.

1.8

News and Social Media Coverage

News Sentiment
Emergent BioSolutions has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Emergent BioSolutions this week, compared to 2 articles on an average week.
Search Interest
Only 5 people have searched for EBS on MarketBeat in the last 30 days. This is a decrease of -89% compared to the previous 30 days.
MarketBeat Follows
Only 6 people have added Emergent BioSolutions to their MarketBeat watchlist in the last 30 days. This is a decrease of -45% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Emergent BioSolutions insiders have not sold or bought any company stock.
Percentage Held by Insiders
11.10% of the stock of Emergent BioSolutions is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
78.40% of the stock of Emergent BioSolutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Emergent BioSolutions are expected to grow in the coming year, from ($13.98) to ($0.25) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Emergent BioSolutions is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Emergent BioSolutions is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Emergent BioSolutions has a P/B Ratio of 0.16. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

Click here to see the details.

About Emergent BioSolutions Stock (NYSE:EBS)

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

EBS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

EBS Stock News Headlines

April 13, 2024 | americanbankingnews.com

Emergent BioSolutions (NYSE:EBS) Stock Rating Reaffirmed by Benchmark

April 1, 2024 | finance.yahoo.com

Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive

April 16, 2024 | InvestorPlace (Ad)

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

March 28, 2024 | globenewswire.com

Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis

March 27, 2024 | bizjournals.com

Why this Maryland biotech furloughed 130 workers in Michigan

March 25, 2024 | globenewswire.com

Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility

March 12, 2024 | marketwatch.com

Emergent BioSolutions Shares Drop on S&P Downgrade

March 7, 2024 | realmoney.thestreet.com

Benchmark gets more bullish on Emergent BioSolutions, upgrades shares

April 16, 2024 | InvestorPlace (Ad)

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

March 7, 2024 | realmoney.thestreet.com

Emergent BioSolutions upgraded to Buy at Benchmark after 'upbeat' Q4 report

March 7, 2024 | finance.yahoo.com

Emergent BioSolutions Inc (EBS) Reports Mixed Fourth Quarter and Full Year 2023 Financial Results

March 7, 2024 | finance.yahoo.com

Emergent BioSolutions Inc. (NYSE:EBS) Q4 2023 Earnings Call Transcript

March 7, 2024 | finance.yahoo.com

Q4 2023 Emergent BioSolutions Inc Earnings Call

March 7, 2024 | fool.com

Emergent BioSolutions (EBS) Q4 2023 Earnings Call Transcript

March 6, 2024 | investorplace.com

EBS Stock Earnings: Emergent BioSolutions Misses EPS, Misses Revenue for Q4 2023

March 6, 2024 | benzinga.com

Emergent BioSolutions: Q4 Earnings Insights

March 6, 2024 | globenewswire.com

Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results

March 6, 2024 | globenewswire.com

Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results

March 6, 2024 | msn.com

Emergent Biosolutions Q4 2023 Earnings Preview

March 4, 2024 | benzinga.com

Emergent BioSolutions's Earnings: A Preview

February 29, 2024 | globenewswire.com

Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024

February 27, 2024 | seekingalpha.com

New CEO Appointment A Clear Positive For Emergent BioSolutions

February 21, 2024 | bizjournals.com

Biotech with Baltimore facility taps new CEO

February 21, 2024 | investorplace.com

Why Is Emergent BioSolutions (EBS) Stock Up 70% Today?

February 21, 2024 | investorplace.com

Why Is Emergent BioSolutions (EBS) Stock Up 70% Today?

February 21, 2024 | msn.com

Teladoc Health, Avinger among healthcare movers

February 21, 2024 | markets.businessinsider.com

Emergent BioSolutions Gains 95% Following Announcement Of Joseph Papa As New CEO

See More Headlines

Receive EBS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emergent BioSolutions and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/06/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Current Symbol: NYSE:EBS
CUSIP: 29089Q10
CIK: 1367644
Web: www.emergentbiosolutions.com
Phone: (240) 631-3200
Fax: 301-795-1899
Employees: 1,600
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.00
High Stock Price Target: $5.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +153.5%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($14.83)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-760,500,000.00
Net Margins: -72.11%
Pretax Margin: -69.68%
Return on Equity: -37.35%
Return on Assets: -14.81%

Debt

Debt-to-Equity Ratio: 0.69
Current Ratio: 1.04
Quick Ratio: 0.54

Sales & Book Value

Annual Sales: $1.05 billion
Price / Sales: 0.10
Cash Flow: $0.84 per share
Price / Cash Flow: 2.34
Book Value: $12.51 per share
Price / Book: 0.16

Miscellaneous

Outstanding Shares: 52,390,000
Free Float: 46,576,000
Market Cap: $103.32 million
Optionable: Optionable
Beta: 1.20

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Richard S. Lindahl M.B.A. (Age 60)
Executive VP, CFO & Treasurer
Comp: $799.38k
Ms. Jennifer L. Fox
Executive VP of External Affairs, General Counsel & Corporate Secretary
Mr. Joseph C. Papa Jr. (Age 68)
CEO & President
Mr. Robert G. Burrows
Vice President of Investor Relations
Ms. Coleen Glessner
Executive Vice President of Global Quality and Ethics & Compliance
Michelle Pepin
Senior VP & Chief Human Resource Officer
Ms. Stephanie Duatschek
Senior VP, Chief Strategy & Transformation Officer
Dr. Kelly Lyn Warfield
Senior VP of Science & Development
Mr. Paul A. Williams
Senior Vice President of Products Business
William Hartzel
Senior Vice President of Manufacturing & Bioservices

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

EBS Stock Analysis - Frequently Asked Questions

Should I buy or sell Emergent BioSolutions stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Emergent BioSolutions in the last year. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" EBS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EBS, but not buy additional shares or sell existing shares.
View EBS analyst ratings or view top-rated stocks.
What is Emergent BioSolutions' stock price target for 2024?: 2 brokerages have issued 12 month price targets for Emergent BioSolutions' shares. Their EBS share price targets range from $5.00 to $5.00. On average, they predict the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 153.2% from the stock's current price.
View analysts price targets for EBS or view top-rated stocks among Wall Street analysts.
How have EBS shares performed in 2024?: Emergent BioSolutions' stock was trading at $2.40 on January 1st, 2024. Since then, EBS shares have decreased by 17.7% and is now trading at $1.9750.
View the best growth stocks for 2024 here.
Are investors shorting Emergent BioSolutions?: Emergent BioSolutions saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 5,700,000 shares, an increase of 16.1% from the March 15th total of 4,910,000 shares. Based on an average daily volume of 2,980,000 shares, the days-to-cover ratio is currently 1.9 days. Approximately 11.4% of the company's shares are short sold.
View Emergent BioSolutions' Short Interest.
When is Emergent BioSolutions' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our EBS earnings forecast.
How were Emergent BioSolutions' earnings last quarter?: Emergent BioSolutions Inc. (NYSE:EBS) announced its quarterly earnings results on Wednesday, March, 6th. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by $0.44. The biopharmaceutical company had revenue of $276.60 million for the quarter, compared to analysts' expectations of $247.63 million. Emergent BioSolutions had a negative trailing twelve-month return on equity of 37.35% and a negative net margin of 72.11%. During the same period last year, the firm posted ($0.31) earnings per share.

What ETF holds Emergent BioSolutions' stock?: Amplify Treatments, Testing and Advancements ETF holds 14,243 shares of EBS stock, representing 0.70% of its portfolio.
What guidance has Emergent BioSolutions issued on next quarter's earnings?: Emergent BioSolutions issued an update on its first quarter 2024 earnings guidance on Wednesday, March, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $200.0 million-$250.0 million, compared to the consensus revenue estimate of $185.4 million.
What is Bob Kramer's approval rating as Emergent BioSolutions' CEO?: 38 employees have rated Emergent BioSolutions Chief Executive Officer Bob Kramer on Glassdoor.com. Bob Kramer has an approval rating of 74% among the company's employees.
What other stocks do shareholders of Emergent BioSolutions own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent BioSolutions investors own include NVIDIA (NVDA), Salesforce (CRM), Novavax (NVAX), Advanced Micro Devices (AMD), Block (SQ), Netflix (NFLX), Gilead Sciences (GILD), PayPal (PYPL), Johnson & Johnson (JNJ) and AbbVie (ABBV).
Who are Emergent BioSolutions' major shareholders?: Emergent BioSolutions' stock is owned by many different retail and institutional investors. Top institutional investors include Los Angeles Capital Management LLC (0.37%). Insiders that own company stock include Kathryn C Zoon, Richard S Lindahl and Ronald Richard.
View institutional ownership trends.
How do I buy shares of Emergent BioSolutions?: Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:EBS) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Emergent BioSolutions (EBS) Stock Price, News & Analysis

Emergent BioSolutions MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Emergent BioSolutions Stock (NYSE:EBS)

EBS Stock Price History

EBS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

EBS Stock Analysis - Frequently Asked Questions

Overall MarketRank^™